Literature DB >> 15785899

Terminal ileal stricture in Crohn's disease: treatment using a metallic enteral endoprosthesis.

S J Bickston1, E Foley, C Lawrence, T Rockoff, H A Shaffer, P Yeaton.   

Abstract

Enteral strictures are a frequent indication for surgery in Crohn's disease. Postoperative complications are increased in patients with poor preoperative nutritional status, which is common in this patient population. We present a 49-year-old female with longstanding Crohn's disease admitted to our Digestive Health Center with four weeks of increasing abdominal symptoms and radiographic evidence of small-bowel obstruction caused by ileal stricture. Given her poor nutritional status, our team elected to pursue metallic enteral stenting as a bridge to surgical resection. Two Wallstents were placed; luminal patency was subsequently confirmed by a fluoroscopic study. The patient tolerated regular diet and was discharged. When seen in follow-up, she remained asymptomatic and wished to defer surgical intervention indefinitely.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15785899     DOI: 10.1007/s10350-004-0865-8

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  3 in total

Review 1.  The role of stents in the treatment of Crohn's disease strictures.

Authors:  Carme Loras Alastruey; Xavier Andújar Murcia; Maria Esteve Comas
Journal:  Endosc Int Open       Date:  2016-03

Review 2.  Feasibility and safety of self-expandable metal stent in nonmalignant disease of the lower gastrointestinal tract.

Authors:  Ludovica Venezia; Andrea Michielan; Giovanna Condino; Emanuele Sinagra; Elisa Stasi; Marianna Galeazzi; Carlo Fabbri; Andrea Anderloni
Journal:  World J Gastrointest Endosc       Date:  2020-02-16

Review 3.  Futuristic Developments and Applications in Endoluminal Stenting.

Authors:  Joel Ferreira-Silva; Renato Medas; Mohit Girotra; Monique Barakat; James H Tabibian; Eduardo Rodrigues-Pinto
Journal:  Gastroenterol Res Pract       Date:  2022-01-11       Impact factor: 2.260

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.